Jon Travers

1.3k citations

23 papers · 659 indexed · h-index 9

Impact in

Oncology top 10%
- PARP inhibition in cancer therapy
- Cancer-related Molecular Pathways
- Cancer Immunotherapy and Biomarkers
Molecular Biology
- DNA Repair Mechanisms
- CRISPR and Genetic Engineering
- Heat shock proteins research
- Ubiquitin and proteasome pathways

Papers in ⓘ

Molecular Biology 13
- Protein Degradation and Inhibitors 4
Oncology 13
- Cancer-related Molecular Pathways 4
- CAR-T cell therapy research 3
- PARP inhibition in cancer therapy 2

Co-authors: Paul Workman (5 shared papers)Swee Y. Sharp (1 shared paper)Stephen P. Jackson (2 shared papers)Satpal S. Jhujh (1 shared paper)Qian Wu (1 shared paper)Carol V. Robinson (1 shared paper)Shahid Mehmood (1 shared paper)Julia Coates (1 shared paper)
Journals: Blood (4 papers)Molecular Cancer Therapeutics (3 papers)Cancer Research (3 papers)Cell Death and Disease (2 papers)Nature Communications (2 papers)
Partner nations: United Kingdom United States Australia

In The Last Decade

Jon Travers

21 papers receiving 651 citations

Peers

Countries citing papers authored by Jon Travers

Since Specialization

Citations

This map shows the geographic impact of Jon Travers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jon Travers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jon Travers more than expected).

Fields of papers citing papers by Jon Travers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jon Travers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jon Travers. The network helps show where Jon Travers may publish in the future.

Co-authors

The 25 scholars most cited alongside Jon Travers, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jon Travers Line = papers co-authored together Jon Travers links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 23 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	PAXX, a paralog of XRCC4 and XLF, interacts with Ku to promote DNA double-strand break repair Science ·Takashi Ochi, Andrew N. Blackford, Julia Coates, Satpal S. Jhujh, Shahid Mehmood, Naoka Tamura, Jon Travers, Qian Wu, Viji M. Draviam, Carol V. Robinson, Tom L. Blundell, Stephen P. Jackson	2015	237
2	Drug ranking using machine learning systematically predicts the efficacy of anti-cancer drugs Nature Communications ·Henry Gerdes, Pedro Casado, Arran Dokal, Maruan Hijazi, Nosheen Akhtar, Ruth Osuntola, Vinothini Rajeeve, Jude Fitzgibbon, Jon Travers, D. Britton, Shirin Elizabeth Khorsandi, Pedro R. Cutillas	2021	84
3	HSP90 inhibition: two-pronged exploitation of cancer dependencies Drug Discovery Today ·Jon Travers, Swee Y. Sharp, Paul Workman	2011	84
4	A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D Oncogene ·Sydonia Rayter, Richard Elliott, Jon Travers, M.G. Rowlands, Tobias B. Richardson, K. Boxall, Keith Jones, Spiros Linardopoulos, Paul Workman, Wynne Aherne, Christopher J. Lord, Alan Ashworth	2007	66
5	Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing’s Sarcoma PLoS ONE ·Sonja J. Gill, Jon Travers, Irina Pshenichnaya, Fiona Kogera, Syd Barthorpe, Tatiana Mironenko, Laura Richardson, Cyril H. Benes, Michael R. Stratton, Ultan McDermott, Stephen P. Jackson, Mathew J. Garnett	2015	62
6	TSR-033, a Novel Therapeutic Antibody Targeting LAG-3, Enhances T-Cell Function and the Activity of PD-1 Blockade In Vitro and In Vivo Molecular Cancer Therapeutics ·Srimoyee Ghosh, Geeta Sharma, Jon Travers, Sujatha Kumar, Justin Choi, H. Toni Jun, Marilyn R. Kehry, Sridhar Ramaswamy, David W. Jenkins	2018	50
7	The discovery of potent ribosomal S6 kinase inhibitors by high-throughput screening and structure-guided drug design Oncotarget ·S. Couty, Isaac M. Westwood, Andrew Kalusa, Céline Cano, Jon Travers, Kathy Boxall, Chiau Ling Chow, Sam Burns, Jessica Schmitt, Lisa Pickard, Caterina Barillari, Craig McAndrew, Paul A. Clarke, Spiros Linardopoulos, Roger J. Griffin, G. Wynne Aherne, Florence I. Raynaud, Paul Workman, Keith Jones, Rob L. M. van Montfort	2013	17
8	Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer Clinical Cancer Research ·Kavya Ramkumar, Azusa Tanimoto, Carminia M. Della Corte, C. Allison Stewart, Qi Wang, Li Shen, Robert J. Cardnell, Jing Wang, Urszula M. Polanska, Courtney L. Andersen, Jamal Saeh, J. Elizabeth Pease, Jon Travers, Giulia Fabbri, Carl M. Gay, Jelena Urosevic, Lauren A. Byers	2023	14
9	Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor Immunity Molecular Cancer Therapeutics ·James A. Harper, Shannon Burke, Jon Travers, Nicola Rath, Andrew Leinster, Christel Navarro, Ruth Franks, Rebecca Leyland, Kathy Mulgrew, Kelly McGlinchey, Lee R. Brown, Simon J. Dovedi, Jens‐Oliver Koopmann, Nicholas M. Durham, Xing Cheng, Hong Jin, Jim Eyles, Robert W. Wilkinson, Danielle Carroll	2021	10
10	Drug-tolerant insurgents Nature ·Paul Workman, Jon Travers	2010	7
11	Targeting leukemia on the DOT Nature Chemical Biology ·Jon Travers, Julian Blagg, Paul Workman	2011	5
12	Aurora B inhibitors promote RB hypophosphorylation and senescence independent of p53-dependent CDK2/4 inhibition Cell Death and Disease ·Shivam Vora, Ariel Andrew, Ramyashree Prasanna Kumar, Deborah Nazareth, Alexis Bonfim‐Melo, Yoon Lim, Xin Yee Ong, Madushan Fernando, Yaowu He, John D. Hooper, Nigel A.J. McMillan, Jelena Urosevic, Jon Travers, Jamal Saeh, Sharad Kumar, Mathew V. Jones, Brian Gabrielli	2024	4
13	Differential ABC transporter expression during hematopoiesis contributes to neutrophil-biased toxicity of Aurora kinase inhibitors Nature Communications ·David B. Chou, Brooke A. Furlong, Ryan R. Posey, Christos Kyprianou, Lucy R. O’Sullivan, Rhiannon David, Suzanne J. Randle, Urszula M. Polanska, Jon Travers, Jelena Urosevic, John N. Hutchinson, Jianwei Che, Anna M. Howley, Robert P. Hasserjian, Rachelle Prantil‐Baun, Donald E. Ingber	2022	4
14	Activity of the novel Aurora kinase B inhibitor AZD2811 in biomarker-defined models of small cell lung cancer Annals of Oncology ·Carminia Maria Della Corte, L. Ajpacaja, Robert J. Cardnell, C.M. Gay, Qianxia Wang, Li Shen, Kavya Ramkumar, Allison Stewart, You Hong Fan, Carrie A. Adelman, Jon Travers, Jie Wang, John V. Heymach, Lauren A. Byers	2019	4
15	A Phase I/II Study of AZD2811 Nanoparticles (NP) As Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory AML/MDS Patients Not Eligible for Intensive Induction Therapy Blood ·William B. Donnellan, Ehab Atallah, Adam S. Asch, Manish R. Patel, Jay Yang, Alireza Eghtedar, Gautam Borthakur, Julie Charlton, Alexander MacDonald, Anna Korzeniowska, Elizabeth Sainsbury, Donald K. Strickland, Suzanne F. Jones, Philip Overend, Carrie A. Adelman, Giulia Fabbri, Jon Travers, Simon A. Smith, J. Elizabeth Pease, Jan Cosaert	2019	4
16	Aurora B inhibition induces hyper-polyploidy and loss of long-term proliferative potential in RB and p53 defective cells Cell Death and Disease ·Shivam Vora, Saptarshi Chatterjee, Ariel Andrew, Ramyashree Prasanna Kumar, Martina Proctor, Zhen Zeng, Rituparna Bhatt, Deborah Nazareth, Madushan Fernando, Mathew V. Jones, Yaowu He, John D. Hooper, Nigel A.J. McMillan, Jelena Urosevic, Jamal Saeh, Jon Travers, Daniela Cimini, Jing Chen, Brian Gabrielli	2025	2
17	Abstract 2234: Exploring the oncolytic potential of Newcastle Disease Virus Cancer Research ·James A. Harper, Jon Travers, Ruth Franks, Shannon Burke, Christel Navarro, Xing Cheng, Weijia Wang, Qi Xu, Robert W. Wilkinson, Hong Jin, Danielle Carroll	2016	1
18	A Phase I/II, Open-Label, Multicentre 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticle As Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory Acute Myeloid Leukaemia/Myelodysplastic Syndrome Patients Not Eligible for Intensive Induction Therapy Blood ·William B. Donnellan, Ehab Atallah, Adam S. Asch, Manish R. Patel, Julie Charlton, Alexander MacDonald, Elena Young, Elizabeth Sainsbury, Donald K. Strickland, Suzanne F. Jones, Philip Overend, Carrie A. Adelman, Jon Travers, Simon A. Smith, J. Elizabeth Pease, Wolfram Brugger	2018	1
19	Abstract 5334: Oncolytic Newcastle disease virus: armed but not dangerous Cancer Research ·Danielle Carroll, James A. Harper, Shannon Burke, Jon Travers, Ruth Franks, Christel Navarro, Xing Cheng, Robert W. Wilkinson, Hong Jin	2015	1
20	Identification of Novel Combination Therapies Active in BCL2 Inhibitor-Resistant Patient-Derived AML Models Blood ·Courtney L. Andersen, Amanda L. Christie, Alan Rosen, Kim Maratea, Maureen M. Hattersley, Jon Travers, Justin Cidado, Sai Murali Krishna Pulukuri, Jamal Saeh, Edwin Clark, Corinne Reimer, Jerome T. Mettetal	2019	1

About Jon Travers

Jon Travers is a scholar working on Molecular Biology, Oncology, Cell Biology, Hematology and Genetics, having authored 23 papers that have together received 659 indexed citations. Recurring topics across this work include Microtubule and mitosis dynamics (9 papers), Protein Degradation and Inhibitors (4 papers), Acute Myeloid Leukemia Research (4 papers), Cancer-related Molecular Pathways (4 papers), Virus-based gene therapy research (3 papers), CAR-T cell therapy research (3 papers), Plant nutrient uptake and metabolism (2 papers) and PARP inhibition in cancer therapy (2 papers). The work is most often cited by research in Oncology (270 citations), Molecular Biology (501 citations), Cancer Research (80 citations), Computational Theory and Mathematics (63 citations) and Cell Biology (53 citations). Jon Travers has collaborated with scholars based in United Kingdom, United States and Australia. Frequent co-authors include Paul Workman, Swee Y. Sharp, Stephen P. Jackson, Satpal S. Jhujh, Qian Wu, Carol V. Robinson, Shahid Mehmood, Julia Coates, Takashi Ochi and Naoka Tamura. Their work appears in journals such as Blood, Molecular Cancer Therapeutics, Cancer Research, Cell Death and Disease and Nature Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact